Company Directory

Controlled-release orthobiologics for spinal fusion and bone repair

Locate Bio is a clinical-stage biotechnology company developing a portfolio of orthobiologic products for musculoskeletal surgery. Its proprietary Programmed Drug Release platform encapsulates recombinant proteins within biodegradable polymer scaffolds to enable controlled, extended-release delivery. Lead product LDGraft is an rhBMP-2 bone graft substitute in clinical trial for lumbar interbody fusion, having received FDA Breakthrough Device Designation. The pipeline also includes synthetic bone graft substitutes and antibiotic-eluting scaffolds for osteomyelitis.

Bio-based polyurethane alternatives from agricultural waste and seaweed

AlGreen is an industrial biotechnology company developing bio-based alternatives to petroleum-derived polyurethanes, which account for approximately 8% of global plastics. Using biotechnology, chemistry, and materials science, the company synthesises fully biodegradable, high-performance polyurethane substitutes from agricultural waste and non-edible plant oils. Products are being commercialised across cosmetics, fashion, packaging, automotive, and medical manufacturing. The company has also developed a seaweed-derived formaldehyde alternative for the furniture industry.

Contract development and manufacture of nanofibrous biomaterials for medical devices

The Electrospinning Company designs, develops, and manufactures nanofibrous biomaterials for implantable medical devices and regenerative medicine applications. Using electrospinning technology, the company produces four proprietary membrane platforms: resorbable Mimetix, permanent Kalyptix, biosynthetic Symatix, and the Caladrix device-coating system. Services span early feasibility through to validated commercial-scale manufacturing under ISO 13485 accreditation, supporting clients across cardiovascular, orthopaedic, wound care, and ophthalmology applications. The company operates from a purpose-built cleanroom facility on Harwell Campus.

Asymmetric biomaterial skin substitutes for acute and chronic wounds

Janus Biosciences is a biotech developing novel biomaterial skin substitutes for the treatment of acute and chronic wounds. The platform is based on asymmetric Janus material architectures, in which opposing faces of the scaffold present distinct physicochemical properties to simultaneously support wound bed healing and provide external barrier protection. The company's goal is to produce universally compatible, widely accessible skin substitutes applicable across a range of wound types and clinical settings.

Oxygen-generating nanoparticles to overcome hypoxia in solid tumours

StimOxyGen is a preclinical-stage biotechnology company developing pH-responsive nanoparticle formulations to address tumour hypoxia, a major barrier to effective cancer treatment. The technology uses a biodegradable polymer coating that dissolves in the acidic tumour microenvironment, transiently generating localised molecular oxygen to sensitise solid tumours to radiotherapy and chemotherapy. The platform also supports delivery of additional therapeutic payloads.

Synthetic platform for precision delivery of biologics in tissue repair

Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable, biocompatible and degradable formulations that retain active molecules at the delivery site, reducing required doses and improving safety for potent therapeutics and biologics. Applications span tissue repair, orthopaedics and spinal fusion.

Bioabsorbable polymer biomaterials for implantable medical devices

4D Medicine is a UK-based biotechnology company developing bioabsorbable polymer biomaterials for use in implantable medical devices and controlled drug delivery systems. The company’s proprietary polymer platform is designed to enable the creation of degradable medical device components with tunable mechanical properties and controlled degradation profiles. 4D Medicine focuses on supplying advanced biomaterials for applications including orthopaedic, cardiovascular and soft tissue repair devices, as well as drug-device combination products.

Silicon-based RNA delivery platform for rare disease therapeutics

SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads. The platform addresses known limitations of conventional lipid nanoparticle delivery systems. SiSaf's internal pipeline targets rare genetic disorders and oncology, and the company licenses its delivery technology to pharmaceutical partners across a range of indications.

Sustained-release ocular drug delivery for retinal disease

Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery technologies for the treatment of serious retinal diseases. Its biodegradable hydrogel platform uses photo-crosslinking to form in-situ implants administered via intravitreal injection, enabling controlled release of biologics, peptides, and small molecules for up to twelve months. Target indications include age-related macular degeneration, diabetic retinopathy, and glaucoma. The technology is also being evaluated through partnerships with global pharmaceutical companies.